NASDAQ:CYTX - Cytori Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.26 -0.02 (-7.14 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$0.28
Today's Range$0.26 - $0.28
52-Week Range$0.22 - $1.21
Volume412,639 shs
Average Volume1.14 million shs
Market Capitalization$16.88 million
P/E Ratio-0.41
Dividend YieldN/A
Beta3.1

About Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics logoCytori Therapeutics, Inc., a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types. The company's second nanomedicine drug candidate is, ATI-1123, a novel and new chemical entity, which has completed Phase I clinical trial and is a workhorse chemotherapeutic drug used for various cancers. It also sells Celution cell processing systems, StemSource cell and tissue banking systems, and surgical accessories and instrumentation to hospitals, clinics, physicians, researchers, and other customers for commercial and research purposes through a combination of a direct sales force, third-party distributors, independent sales representatives, and licensees. In addition, the company markets and sells its proprietary enzymatic reagents under the Celase and Intravase brands. It has operations in the Americas, Japan, EMEA, and the Asia Pacific. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CYTX
CUSIP23283K10
Phone858-458-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio0.60
Quick Ratio0.42

Price-To-Earnings

Trailing P/E Ratio-0.41
Forward P/E Ratio-1.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.69 million
Price / Sales5.95
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book1.86

Profitability

EPS (Most Recent Fiscal Year)($0.65)
Net Income$-22,680,000.00
Net Margins-428.14%
Return on Equity-190.35%
Return on Assets-65.83%

Miscellaneous

Employees37
Outstanding Shares61,610,000

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics's stock reverse split on the morning of Thursday, May 12th 2016. The 1-15 reverse split was announced on Thursday, May 12th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 11th 2016. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics (NASDAQ:CYTX) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.03. The biotechnology company earned $0.73 million during the quarter, compared to the consensus estimate of $2.43 million. Cytori Therapeutics had a negative net margin of 428.14% and a negative return on equity of 190.35%. During the same period in the previous year, the company earned ($0.24) earnings per share. View Cytori Therapeutics' Earnings History.

When is Cytori Therapeutics' next earnings date?

Cytori Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Cytori Therapeutics.

What price target have analysts set for CYTX?

4 brokers have issued 12 month target prices for Cytori Therapeutics' stock. Their forecasts range from $1.65 to $4.00. On average, they anticipate Cytori Therapeutics' stock price to reach $2.55 in the next year. View Analyst Ratings for Cytori Therapeutics.

What are Wall Street analysts saying about Cytori Therapeutics stock?

Here are some recent quotes from research analysts about Cytori Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (5/15/2018)
  • 2. Maxim Group analysts commented, "Cytori presented data in Ovarian Cancer at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting demonstrating bioequivalence of ATI-0918, generic liposomal formulation of doxorubicin, to J&Js CAELYX (branded EU product). We expect Cytori to file for approval in Europe in 2H18 and the company to partner ATI-0918 for commercialization. We profile the opportunity for liposomal doxorubicin, which was acquired with the acquisition of Azaya earlier in 2017, in the attachment below." (11/13/2017)

Who are some of Cytori Therapeutics' key competitors?

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the folowing people:
  • Dr. Marc H. Hedrick M.D., Pres, CEO & Director (Age 55)
  • Mr. Tiago M. Girao, VP of Fin., CFO & Principal Accounting Officer (Age 39)
  • Mr. John D. Harris, VP & GM of Cell Therapy (Age 49)
  • Dr. John K. Fraser Ph.D., Chief Scientist (Age 57)
  • Mr. Russ Havranek, VP of Global Marketing

Has Cytori Therapeutics been receiving favorable news coverage?

Media coverage about CYTX stock has been trending somewhat positive on Wednesday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a media sentiment score of 0.23 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.65 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Cytori Therapeutics?

Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $0.26.

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $16.88 million and generates $2.69 million in revenue each year. The biotechnology company earns $-22,680,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]


MarketBeat Community Rating for Cytori Therapeutics (CYTX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cytori Therapeutics (NASDAQ:CYTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Cytori Therapeutics in the last 12 months. Their average twelve-month price target is $2.55, suggesting that the stock has a possible upside of 880.77%. The high price target for CYTX is $4.00 and the low price target for CYTX is $1.65. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.55$1.9833$2.65$3.65
Price Target Upside: 880.77% upside561.11% upside679.41% upside886.49% upside

Cytori Therapeutics (NASDAQ:CYTX) Consensus Price Target History

Price Target History for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ:CYTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018HC WainwrightSet Price TargetBuy$4.00MediumView Rating Details
5/11/2018Maxim GroupSet Price TargetBuy$2.00LowView Rating Details
3/9/2018B. RileyUpgradeNeutral ➝ BuyLowView Rating Details
2/22/2018LaidlawReiterated RatingBuy ➝ Buy$1.65MediumView Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Cytori Therapeutics (NASDAQ:CYTX) Earnings History and Estimates Chart

Earnings by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ:CYTX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.06)($0.06)($0.06)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.04)($0.04)($0.04)
Q4 20181($0.04)($0.04)($0.04)

Cytori Therapeutics (NASDAQ CYTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2018        
5/10/2018Q1 2018($0.04)($0.07)$2.43 million$0.73 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.0850)($0.10)$2.00 million$1.50 millionViewListenView Earnings Details
11/9/2017Q3 17($0.16)($0.14)$2.04 million$1.77 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.16)($0.18)$2.23 million$0.90 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.31)($0.26)$2.32 million$0.60 millionViewN/AView Earnings Details
3/23/2017Q4 16($0.23)($0.24)$3.36 million$1.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.24)($0.26)$2.85 million$2.61 millionViewListenView Earnings Details
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$2.90 million$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.03)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.09)($0.12)$4.31 million$1.10 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.11)($0.15)$2.76 million$0.94 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)$3.24 million$1.39 millionViewN/AView Earnings Details
3/7/2013Q4 2012($2.25)($1.35)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
8/8/2012Q2 2012($2.10)($1.83)ViewN/AView Earnings Details
5/9/2012Q1 2012($2.40)($2.47)ViewN/AView Earnings Details
3/8/2012Q4 2011($2.25)($2.02)ViewN/AView Earnings Details
11/3/2011Q3 2011($2.40)($2.25)ViewN/AView Earnings Details
8/9/2011Q2 2011($2.25)($2.47)ViewN/AView Earnings Details
5/5/2011Q1 2011($2.40)($2.56)ViewN/AView Earnings Details
3/10/2011Q4 2010($2.55)($2.65)ViewN/AView Earnings Details
11/4/2010Q3 2010($2.25)($3.40)ViewN/AView Earnings Details
8/6/2010Q2 2010($1.80)($1.80)ViewN/AView Earnings Details
5/6/2010Q1 2010($2.40)($0.45)ViewN/AView Earnings Details
3/12/2010Q4 2009($2.40)($2.62)ViewN/AView Earnings Details
11/9/2009Q3 2009($2.25)($2.74)ViewN/AView Earnings Details
8/10/2009Q2 2009($2.25)($0.36)ViewN/AView Earnings Details
5/11/2009Q1 2009($2.70)($3.01)ViewN/AView Earnings Details
3/6/2009Q4 2008($3.75)($3.34)ViewN/AView Earnings Details
11/10/2008Q3 2008($3.75)($3.66)ViewN/AView Earnings Details
8/8/2008Q2 2008($4.05)($4.89)ViewN/AView Earnings Details
5/9/2008Q1 2008($5.25)($5.07)ViewN/AView Earnings Details
3/12/2008Q4 2007($5.25)($6.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cytori Therapeutics (NASDAQ:CYTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cytori Therapeutics (NASDAQ CYTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 7.24%
Insider Trading History for Cytori Therapeutics (NASDAQ:CYTX)
Institutional Ownership by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Cytori Therapeutics (NASDAQ CYTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Ag PostfinanceMajor ShareholderSell286,982$0.31$88,964.425,118,627View SEC Filing  
2/9/2018Ag PostfinanceMajor ShareholderSell236,155$0.34$80,292.705,311,451View SEC Filing  
1/11/2018Bank Sa SwissquoteMajor ShareholderSell72,630$0.34$24,694.205,496,655View SEC Filing  
1/9/2018Bank Sa SwissquoteMajor ShareholderSell100,000$0.38$38,000.005,496,655View SEC Filing  
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.007,000View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.002,400View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.002,000View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.0026,200View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00504,611View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00504,611View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00504,611View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.002,201View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00504,611View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.0088,000View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cytori Therapeutics (NASDAQ CYTX) News Headlines

Source:
DateHeadline
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.
finance.yahoo.com - May 18 at 6:00 PM
Zacks Investment Research Downgrades Cytori Therapeutics (CYTX) to SellZacks Investment Research Downgrades Cytori Therapeutics (CYTX) to Sell
www.americanbankingnews.com - May 15 at 9:18 PM
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $0.55 at Ascendiant CapitalCytori Therapeutics, Inc. (CYTX) PT Lowered to $0.55 at Ascendiant Capital
www.streetinsider.com - May 14 at 5:20 PM
Cytori Therapeutics (CYTX) Given a $4.00 Price Target at HC WainwrightCytori Therapeutics (CYTX) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 14 at 12:42 PM
Cytori Therapeutics (CYTX) Misses Q1 EPS by 1cCytori Therapeutics (CYTX) Misses Q1 EPS by 1c
www.streetinsider.com - May 12 at 8:25 AM
Edited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMTEdited Transcript of CYTX earnings conference call or presentation 10-May-18 9:30pm GMT
finance.yahoo.com - May 12 at 8:25 AM
Cytori Therapeutics (CYTX) Releases  Earnings Results, Misses Expectations By $0.03 EPSCytori Therapeutics (CYTX) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 11 at 11:32 PM
Cytori Therapeutics (CYTX) PT Set at $2.00 by Maxim GroupCytori Therapeutics (CYTX) PT Set at $2.00 by Maxim Group
www.americanbankingnews.com - May 11 at 6:12 PM
Cytori Therapeutics (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call TranscriptCytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 5:58 PM
Cytori: 1Q Earnings SnapshotCytori: 1Q Earnings Snapshot
finance.yahoo.com - May 11 at 8:27 AM
$2.43 Million in Sales Expected for Cytori Therapeutics (CYTX) This Quarter$2.43 Million in Sales Expected for Cytori Therapeutics (CYTX) This Quarter
www.americanbankingnews.com - May 11 at 1:46 AM
Cytori Reports Q1 2018 Business and Financial ResultsCytori Reports Q1 2018 Business and Financial Results
finance.yahoo.com - May 10 at 5:57 PM
Cytori Therapeutics (CYTX) Upgraded at Zacks Investment ResearchCytori Therapeutics (CYTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 9 at 9:42 PM
Cytori Therapeutics (CYTX) Scheduled to Post Quarterly Earnings on ThursdayCytori Therapeutics (CYTX) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 8 at 9:34 AM
Cytori to Webcast First Quarter Financial Results on May 10Cytori to Webcast First Quarter Financial Results on May 10
finance.yahoo.com - May 7 at 5:38 PM
Cytori Therapeutics (CYTX) Earns Buy Rating from Analysts at HC WainwrightCytori Therapeutics (CYTX) Earns Buy Rating from Analysts at HC Wainwright
www.americanbankingnews.com - May 7 at 2:56 PM
Cytori Therapeutics (CYTX) Given Average Rating of "Hold" by AnalystsCytori Therapeutics (CYTX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 7 at 11:54 AM
Analysts Expect Cytori Therapeutics (CYTX) to Announce ($0.05) Earnings Per ShareAnalysts Expect Cytori Therapeutics (CYTX) to Announce ($0.05) Earnings Per Share
www.americanbankingnews.com - May 6 at 3:32 AM
Cytori Therapeutics (CYTX) Rating Increased to Sell at ValuEngineCytori Therapeutics (CYTX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 7:56 PM
BRIEF-Cytori Provides Update On US Manufacturing And EU Approval Plans For ATI-0918, Liposomal DoxorubicinBRIEF-Cytori Provides Update On US Manufacturing And EU Approval Plans For ATI-0918, Liposomal Doxorubicin
www.reuters.com - May 1 at 5:18 PM
Cytori Therapeutics (CYTX) Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal ...Cytori Therapeutics (CYTX) Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal ...
www.streetinsider.com - May 1 at 5:18 PM
Cytori Updates On US Manufacturing And EU Approval Plans For ATI-0918Cytori Updates On US Manufacturing And EU Approval Plans For ATI-0918
www.nasdaq.com - April 30 at 5:14 PM
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal DoxorubicinCytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
finance.yahoo.com - April 30 at 5:14 PM
Maxim Group Analysts Give Cytori Therapeutics (CYTX) a $2.00 Price TargetMaxim Group Analysts Give Cytori Therapeutics (CYTX) a $2.00 Price Target
www.americanbankingnews.com - April 30 at 2:34 PM
Reviewing Cytori Therapeutics (CYTX) & Restoration Robotics (HAIR)Reviewing Cytori Therapeutics (CYTX) & Restoration Robotics (HAIR)
www.americanbankingnews.com - April 24 at 5:14 PM
Analysts Anticipate Cytori Therapeutics Inc (CYTX) to Announce ($0.05) EPSAnalysts Anticipate Cytori Therapeutics Inc (CYTX) to Announce ($0.05) EPS
www.americanbankingnews.com - April 20 at 9:26 AM
Cytori Therapeutics (CYTX) Given a $10.00 Price Target by Maxim Group AnalystsCytori Therapeutics (CYTX) Given a $10.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 19 at 12:16 PM
Cytori Therapeutics (CYTX) Upgraded at ValuEngineCytori Therapeutics (CYTX) Upgraded at ValuEngine
www.americanbankingnews.com - April 18 at 4:44 PM
B. Riley Lowers Cytori Therapeutics (CYTX) to NeutralB. Riley Lowers Cytori Therapeutics (CYTX) to Neutral
www.americanbankingnews.com - April 16 at 2:58 PM
Cytori Therapeutics (CYTX) Lowered to "Strong Sell" at ValuEngineCytori Therapeutics (CYTX) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 2:31 PM
ValuEngine Downgrades Cytori Therapeutics (CYTX) to Strong SellValuEngine Downgrades Cytori Therapeutics (CYTX) to Strong Sell
www.americanbankingnews.com - April 3 at 5:16 PM
B. Riley Reaffirms Hold Rating for Cytori Therapeutics (CYTX)B. Riley Reaffirms Hold Rating for Cytori Therapeutics (CYTX)
www.americanbankingnews.com - April 1 at 3:10 PM
Comparing Cytori Therapeutics (CYTX) & Restoration Robotics (HAIR)Comparing Cytori Therapeutics (CYTX) & Restoration Robotics (HAIR)
www.americanbankingnews.com - April 1 at 11:08 AM
 Cytori Therapeutics Inc (CYTX) Given $1.45 Average Price Target by Analysts Cytori Therapeutics Inc (CYTX) Given $1.45 Average Price Target by Analysts
www.americanbankingnews.com - March 31 at 3:18 PM
Cytori Therapeutics (CYTX) Stock Rating Upgraded by Zacks Investment ResearchCytori Therapeutics (CYTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 1:07 PM
Cytori Therapeutics (CYTX) Reports Full Enrollment in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary IncontinenceCytori Therapeutics (CYTX) Reports Full Enrollment in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary Incontinence
www.streetinsider.com - March 28 at 5:18 PM
Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary IncontinenceEnrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
finance.yahoo.com - March 28 at 5:18 PM
Blog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of RimegepantBlog Exposure - Biohaven Reported Positive Top-line Results For its Two Pivotal Phase-3 Trials of Rimegepant
finance.yahoo.com - March 28 at 8:27 AM
Cytori Therapeutics (CYTX) Lifted to "Sell" at ValuEngineCytori Therapeutics (CYTX) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Edited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMTEdited Transcript of CYTX earnings conference call or presentation 8-Mar-18 10:30pm GMT
finance.yahoo.com - March 18 at 6:23 PM
Cytori Therapeutics (CYTX) Issues  Earnings ResultsCytori Therapeutics (CYTX) Issues Earnings Results
www.americanbankingnews.com - March 10 at 9:56 AM
Cytori Therapeutics (CYTX) Stock Rating Upgraded by B. RileyCytori Therapeutics (CYTX) Stock Rating Upgraded by B. Riley
www.americanbankingnews.com - March 9 at 8:33 PM
Cytori Therapeutics (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCytori Therapeutics' (CYTX) CEO Marc Hedrick on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:20 AM
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results - GlobeNewswire (press release)Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:20 AM
Cytori reports 4Q lossCytori reports 4Q loss
finance.yahoo.com - March 9 at 8:20 AM
Cytori Therapeutics (CYTX) Stock Rating Lowered by Zacks Investment ResearchCytori Therapeutics (CYTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 8 at 8:48 PM
Want To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed LatelyWant To Invest In Cytori Therapeutics Inc (NASDAQ:CYTX)? Here’s How It Performed Lately
finance.yahoo.com - March 8 at 6:44 PM
Cytori Therapeutics Q4 Earnings PreviewCytori Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 8 at 6:44 PM
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial ResultsCytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
finance.yahoo.com - March 8 at 6:44 PM
FY2017 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)FY2017 EPS Estimates for Cytori Therapeutics Inc Cut by B. Riley (CYTX)
www.americanbankingnews.com - March 8 at 7:54 AM

SEC Filings

Cytori Therapeutics (NASDAQ:CYTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cytori Therapeutics (NASDAQ:CYTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cytori Therapeutics (NASDAQ CYTX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.